ECSP22066670A - 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso - Google Patents

2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso

Info

Publication number
ECSP22066670A
ECSP22066670A ECSENADI202266670A ECDI202266670A ECSP22066670A EC SP22066670 A ECSP22066670 A EC SP22066670A EC SENADI202266670 A ECSENADI202266670 A EC SENADI202266670A EC DI202266670 A ECDI202266670 A EC DI202266670A EC SP22066670 A ECSP22066670 A EC SP22066670A
Authority
EC
Ecuador
Prior art keywords
quinazolin
piperazin
methoxyphenyl
trifluoromethyl
fluoro
Prior art date
Application number
ECSENADI202266670A
Other languages
English (en)
Inventor
Bertran Jordi Carles Ceron
Thomas Goldner
Helmut Buschmann
Original Assignee
Aic246 Ag Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aic246 Ag Co Kg filed Critical Aic246 Ag Co Kg
Publication of ECSP22066670A publication Critical patent/ECSP22066670A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a la nueva 3,4-dihidroquinazolina, 2-[(4S)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4H-quinazolin-4-il] acetato de sodio monohidrato, métodos para su preparación, así como composiciones farmacéuticas que contienen dicha 3,4-dihidroquinazolina. Dicho compuesto es particularmente útil para el tratamiento y prevención de enfermedades asociadas con citomegalovirus (CMV), particularmente citomegalovirus humano (HCMV).
ECSENADI202266670A 2020-02-27 2022-08-24 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso ECSP22066670A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20159709 2020-02-27

Publications (1)

Publication Number Publication Date
ECSP22066670A true ECSP22066670A (es) 2022-12-30

Family

ID=69742712

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202266670A ECSP22066670A (es) 2020-02-27 2022-08-24 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso

Country Status (19)

Country Link
US (1) US20230219900A1 (es)
EP (1) EP4110469A1 (es)
JP (1) JP7579350B2 (es)
CN (1) CN115427111A (es)
AR (1) AR121440A1 (es)
AU (1) AU2021225364B2 (es)
BR (1) BR112022016906A2 (es)
CL (2) CL2022002290A1 (es)
CO (1) CO2022012017A2 (es)
CU (1) CU20220047A7 (es)
EC (1) ECSP22066670A (es)
IL (1) IL295633A (es)
MX (1) MX2022010440A (es)
MY (1) MY210486A (es)
PE (1) PE20230347A1 (es)
PY (1) PY2116987A (es)
TW (1) TWI886221B (es)
UY (1) UY39098A (es)
WO (1) WO2021170879A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR121439A1 (es) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Un método para producir una forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato
UY39097A (es) 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acético
CN119731157A (zh) * 2022-08-15 2025-03-28 上海迪赛诺化学制药有限公司 一种来特莫韦无定形的制备方法
AR134783A1 (es) 2023-12-21 2026-04-01 Aic246 Ag & Co Kg Sales diastereoméricas de aminoalcohol y aminoéter de ácido 2-[(4r,s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-3,4-dihidroquinazolin-4-il]acético y su uso para separación enantiomérica

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) * 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
DE102012101659A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats

Also Published As

Publication number Publication date
CO2022012017A2 (es) 2022-11-18
JP2023519809A (ja) 2023-05-15
EP4110469A1 (en) 2023-01-04
CU20220047A7 (es) 2023-04-10
TWI886221B (zh) 2025-06-11
IL295633A (en) 2022-10-01
TW202140454A (zh) 2021-11-01
AR121440A1 (es) 2022-06-08
US20230219900A1 (en) 2023-07-13
BR112022016906A2 (pt) 2022-12-06
CA3169473A1 (en) 2021-09-02
AU2021225364A1 (en) 2022-10-13
MX2022010440A (es) 2022-10-18
UY39098A (es) 2021-09-30
AU2021225364B2 (en) 2024-11-28
PY2116987A (es) 2021-12-01
WO2021170879A1 (en) 2021-09-02
MY210486A (en) 2025-09-25
JP7579350B2 (ja) 2024-11-07
NZ792571A (en) 2025-07-25
CL2026000473A1 (es) 2026-06-05
CL2022002290A1 (es) 2023-02-03
CN115427111A (zh) 2022-12-02
KR20220147655A (ko) 2022-11-03
PE20230347A1 (es) 2023-03-02

Similar Documents

Publication Publication Date Title
CO2022012017A2 (es) 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso
BRPI0409227C1 (pt) composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
BRPI0409109A (pt) novos compostos
JP2013544893A5 (es)
NZ594589A (en) 3h-imidazo [4, 5 -c] pyridine- 6 -carboxamides as anti- inflammatory agents
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
NO20062905L (no) Nye hydroksaminsyreestere og farmasoytisk anvendelse derav
BRPI0719920B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
JOP20210338A1 (ar) نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد
MX2024002696A (es) Derivados del acido 2-amino-5,5-dimetilhexanoico como moduladores de sortilina para su uso en el tratamiento de enfermedades del sistema nervioso central.
ECSP22066666A (es) Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]- 4h-quinazolin-4-il]acético
BR112014032244A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças associadas com hiperplasia, neoplasia ou displasia, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
AR037427A1 (es) Compuesto de quinolina, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento para prepararlo y compuestos de quinolina de utilidad como intermediarios en dicho procedimiento
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
GEP20257771B (en) Compounds and compositions as sppl2a inhibitors
BRPI0720251B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo
JOP20190278A1 (ar) مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
BRPI0607214B8 (pt) derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação
BRPI0719939B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo
CU20220049A7 (es) Forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato, método para su preparación y composiciones farmacéuticas que la comprenden
GEP20257828B (en) Pharmaceutical compositions comprising 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl) piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate and potassium ions
ZA202405279B (en) Heteroaryl derivative and use thereof